Advertisement


Paul Richardson, MD, on Multiple Myeloma: Results From the OP-106 Horizon Trial

2018 ASH Annual Meeting & Exposition

Advertisement

Paul Richardson, MD, of Dana-Farber Cancer Institute, discusses updated results and the first report on progression-free survival for melflufen therapy administered to people with multiple myeloma that is refractory to daratumumab and/or pomalidomide (Abstract 600).



Related Videos

Leukemia

Jennifer Ann Woyach, MD, on CLL: Results From the Alliance North American Intergroup Study

Jennifer Ann Woyach, MD, of The Ohio State University, discusses trial findings on ibrutinib alone or in combination with rituximab compared with bendamustine plus rituximab in unt...

Leukemia

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Treatment Trial Results

Shaji K. Kumar, MD, of the Mayo Clinic, discusses phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagn...

Lymphoma

Gilles A. Salles, MD, PhD, on DLBCL: Results From the L-Mind Treatment Trial

Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refracto...

Leukemia

Andreas Burchert, MD, on AML: Results From the Sormain Trial

Andreas Burchert, MD, of the Philipps University of Marburg, discusses study findings on sorafenib as maintenance therapy after allogeneic stem cell transplantation for FLT3-IT...

Multiple Myeloma

Francesca M. Gay, MD, on Multiple Myeloma: Results From the Forte Trial

Francesca M. Gay, MD, of GIMEMA, European Myeloma Network, discusses study findings on the use of carfilzomib in induction combination regimens with autologous transplantation, and...

Advertisement

Advertisement



;
Advertisement